Literature DB >> 8263146

Marked effects of sustained low growth hormone (GH) levels on day-to-day fuel metabolism: studies in GH-deficient patients and healthy untreated subjects.

J O Jørgensen1, J Møller, K G Alberti, O Schmitz, J S Christiansen, H Orskov, N Moller.   

Abstract

The metabolic effects of circadian GH levels in the very low physiological range are unknown. Therefore, we studied 1) GH-deficient patients on receiving GH replacement therapy in whom the last GH injection was replaced with a constant iv infusion starting at 24 h of either GH (35 micrograms/h) or saline (SAL), and 2) an untreated healthy control group. Glucose turnover, indirect calorimetry, and forearm exchange of metabolites were investigated the following day in the basal state (8-11 h) and during a euglycemic (11-13 H) and a hypoglycemic (13-14 h) glucose clamp. During infusion, steady state GH levels increased by 1.9 micrograms/L. Basal and insulin-stimulated energy expenditures (EE) were lower in the patients during SAL than during GH infusion, and the basal respiratory exchange ratio was also lower during GH treatment. Protein EE was elevated during SAL compared to GH infusion (P < 0.05). During the clamp, forearm glucose uptake decreased in the GH study compared to that in the SAL study ((P < 0.05). The patients in the SAL study were more sensitive to insulin during the clamp in terms of suppression of endogenous glucose production (EGP; P < 0.05) and infusion rate of glucose necessary to maintain euglycemia (M value; P < 0.01). Lipid oxidation, in particular in the basal state, was decreased during SAL compared to GH infusion (P < 0.01). The SAL-treated compared with the control group was characterized by decreased basal and insulin-stimulated EE (P < 0.01), increased protein EE (P < 0.01), and hypersensitivity to insulin in terms of suppression of EGP (P < 0.05) and M value (P < 0.01). During the hypoglycemic clamp, the patients in the SAL study were hypersensitive to the hypoglycemic actions of insulin in terms of increased M-value and suppression of EGP, and lipolysis was impaired, as judged by the inhibition of net forearm uptake of FFA. In conclusion, very low GH levels exert powerful actions on day-to-day metabolism, resulting in protein and glucose sparing at the expense of lipids.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263146     DOI: 10.1210/jcem.77.6.8263146

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Effects of GH in human muscle and fat.

Authors:  Jens Otto Lunde Jørgensen; Kristine Z Rubeck; Thomas S Nielsen; Berthil F F Clasen; Mikkel Vendelboe; Thomas K Hafstrøm; Michael Madsen; Sten Lund
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

3.  Gender modulates sequential suppression and recovery of pulsatile growth hormone secretion by physiological feedback signals in young adults.

Authors:  Johannes D Veldhuis; Leon Farhy; Arthur L Weltman; Jonathan Kuipers; Judith Weltman; Laurie Wideman
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

4.  Impacts of dietary selenium deficiency on metabolic phenotypes of diet-restricted GPX1-overexpressing mice.

Authors:  Matthew P Pepper; Marko Z Vatamaniuk; Xi Yan; Carol A Roneker; Xin Gen Lei
Journal:  Antioxid Redox Signal       Date:  2010-09-29       Impact factor: 8.401

5.  Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes.

Authors:  Vishva M Sharma; Esben Thyssen Vestergaard; Niels Jessen; Peter Kolind-Thomsen; Birgitte Nellemann; Thomas S Nielsen; Mikkel Holm Vendelbo; Niels Møller; Rita Sharma; Kevin Y Lee; John J Kopchick; Jens Otto Lunde Jørgensen; Vishwajeet Puri
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-16       Impact factor: 4.310

6.  Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.

Authors:  T L Bianda; M A Hussain; A Keller; Y Glatz; O Schmitz; J S Christiansen; K G Alberti; E R Froesch
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

7.  Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load.

Authors:  Thomas Krusenstjerna-Hafstrøm; Michael Madsen; Mikkel H Vendelbo; Steen B Pedersen; Jens S Christiansen; Niels Møller; Niels Jessen; Jens O L Jørgensen
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

8.  Effect of growth hormone treatment on energy expenditure and its relation to first-year growth response in children.

Authors:  Saartje Straetemans; D A Schott; Guy Plasqui; Hilde Dotremont; Angèle J G M Gerver-Jansen; An Verrijken; Klaas Westerterp; Luc J I Zimmermann; Willem-Jan M Gerver
Journal:  Eur J Appl Physiol       Date:  2018-11-26       Impact factor: 3.078

9.  Effects of growth hormone (GH) therapy withdrawal on glucose metabolism in not confirmed GH deficient adolescents at final height.

Authors:  Flavia Prodam; Silvia Savastio; Giulia Genoni; Deepak Babu; Mara Giordano; Roberta Ricotti; Gianluca Aimaretti; Gianni Bona; Simonetta Bellone
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.